US OKs resumed sales of Biogen and Elan's Tysabri
Mon, 05 Jun 2006 05:03 PM EST
... WASHINGTON (Reuters) - Biogen Idec Inc. and Elan Corp. won permission on Monday to resume sales of their multiple sclerosis drug Tysabri, which was withdrawn last year after it was linked to a rare but potentially fatal brain disease, U.S. regulators said. ...

Not Signed In -


